OIS Ophthalmology Innovation Source - Glaucoma Ad - Wide Type 2

Market Overview . Start-Ups . Panel Discussions .


Join OIS on Thursday, October 21st for the Glaucoma Innovation Showcase which includes presentations by the hottest start-ups, and will feature the below panel of rockstar Glaucoma specialists who will discuss & debate:

  • The future of glaucoma surgery: Are MIGS dead?  Is Trabeculectomy dead?
  • Factoring telemedicine into glaucoma treatment.
  • What is to come after visual field testing and how will decisions be made going forward?
  • The impact of advancements in drug delivery.
  • The greatest unmet need in glaucoma today.
Larger Image
Glaucoma Panel


Sahar Bedrood, MD, PhD, Partner – Acuity Eye Group

Leon W. Herndon Jr., MD, Professor of Ophthalmology - Duke University Medical Center

Jeffrey M. Liebmann, MD, Professor of Ophthalmology - Columbia University Medical Center

Ehsan Sadri, MD, FACS, CEO & Founder of Visionary Eye Institute/General Partner, and Co-Founder of Visionary Ventures Fund

Sarah H. Van Tassel, MD, Assistant Professor of Ophthalmology
Glaucoma, Cataracts, and General Eye Diseases - Weill Cornell Medicine


Moderated By:

Robert Rothman, MD - Partner at OCLI/Glaucoma Consultants of Long Island

Co-Founder and Managing Member of InFocus Capital Partners


Gold Sponsor

Bausch + Lomb

Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, is one of the world's best-known and most respected health care brands, solely focused on protecting, enhancing and restoring people's eyesight.

Silver Sponsors

Aerie Pharmaceuticals

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for open-angle glaucoma, ocular surface diseases and retinal diseases. In the U.S., Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie is expanding globally, with offices in Europe and Japan, and a manufacturing facility in Ireland. Rhokiinsa® (netarsudil ophthalmic solution) 0.02% and Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% are approved in the EU. A Phase 3 study of netarsudil ophthalmic solution is underway in Japan, in collaboration with Santen. Aerie is also pursuing additional candidates in ophthalmology, including a Phase 2b dry eye program with AR-15512 (TRPM8 agonist), and two clinical-stage retina programs, AR-1105 (dexamethasone) Sustained Release Implant and AR-13503 (Rho kinase/Protein kinase C inhibitor) Sustained Release Implant. Aerie continues to investigate assets from its proprietary library of small-molecule multi-kinase inhibitors.


Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Through Surgical, Pharmaceutical and Vision Care, Alcon offers the world’s widest spectrum of ophthalmic products, helping millions of patients see the world better with clarity, color and beauty.


Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics.

Promedica International

Promedica International is a privately held, full-service, ISO-certified CRO providing clinical trial services for the medical device, biotechnology and pharmaceutical industries. Founded in 1985, Promedica International, a woman-owned corporation, is headquartered in Orange County, California. We have successfully been providing exceptional value to our clients for over 30 years in clinical trial project management, site recruitment and management, clinical study monitoring, data management, biostatistics, medical writing and GCP auditing.

Bronze Sponsors


Nicox is an international ophthalmic company, with two out-licensed commercial-stage products, developing innovative solutions to help maintain vision and improve ocular health. The Company’s strategy is to maximise the potential of its proprietary nitric oxide (NO)-donating research platform and its products and product candidates through in-house development and industry-leading collaborations.

Sun Ophthalmics

Sun Ophthalmics is reenergizing eye care. We are a US division of Sun Pharma, a global specialty pharmaceutical corporation with operations in over 150 countries. Our mission is to launch innovative ophthalmic products that complement your approach to treatment. We focus on your unmet treatment needs in patient care so you can focus on your patients. Discover a brighter future in eye care. For more information on our products and vision, visit www.SunOphthalmics.com.



Get the Latest News, Podcasts and Videos.